Cost-effectiveness of single-dose AmBisome pre-emptive treatment for the prevention of cryptococcal meningitis in African low and middle-income countries

Keyphrases

• Cost-effectiveness 100%
• Cryptococcal Meningitis 100%
• Preemptive Treatment 100%
• Low-middle Income Countries 100%
• AmBisome 100%
• Fluconazole 58%
• Preemptive Therapy 58%
• Cryptococcal Antigen 41%
• Uganda 33%
• Antigen Screening 25%
• South Africa 25%
• Disability-adjusted Life Years 25%
• Meningitis 16%
• Low-income Settings 16%
• Clinical Trials 8%
• HIV Patients 8%
• Africa 8%
• Monotherapy 8%
• Observatory Data 8%
• Screening Study 8%
• Hospitalization 8%
• Cost Savings 8%
• Global Health 8%
• Low-income Countries 8%
• Advanced HIV Disease 8%
• Life Expectancy 8%
• Decision-analytic Model 8%
• Age-specific 8%
• Middle-income Countries 8%
• Discount Price 8%
• Failure Rate 8%
• Hospital Costs 8%
• AIDS-related Deaths 8%
• Liposomal Amphotericin B 8%
• GDP per Capita 8%
• Lay Summary 8%
• Price Range 8%
• Middle-income Setting 8%
• Health Observatory 8%
• Free Survival 8%

Medicine and Dentistry

• Health Care Cost 100%
• Cost-Effectiveness Analysis 100%
• Single Drug Dose 100%
• Cryptococcal Meningitis 100%
• Amphotericin B Lipid Complex 100%
• Low and Middle Income Countries 100%
• Fluconazole 58%
• Disability Adjusted Life Years 25%
• Antigen 25%
• Meningitis 16%
• Human Immunodeficiency Virus 16%
• Clinical Trial 8%
• Monotherapy 8%
• Life Expectancy 8%
• Amphotericin B 8%
• Head 8%